KYMERA THERAPEUTICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- KYMERA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $13.38M, a 73.74% increase year-over-year.
- KYMERA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $19.19M, a 3487.66% increase year-over-year.
- KYMERA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $48.83M, a 2146.18% increase year-over-year.
- KYMERA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $4.55M, a 9.90% decline year-over-year.
- KYMERA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $61.62M, a 422.65% increase from fiscal 2024.
- KYMERA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $11.79M, a 312.24% increase from fiscal 2023.
- KYMERA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $2.86M, a 9.32% decline from fiscal 2022.
- KYMERA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $3.15M, a 58.68% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $13.38M 10-Q · filed 2026-08-05 | $85.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $19.19M 10-Q · filed 2026-04-30 | $80.28M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $48.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $61.62M 10-K · filed 2026-02-26 |
| 2025-09-30 | $4.55M 10-Q · filed 2025-11-04 | $14.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $7.70M 10-Q · filed 2026-08-05 | $15.46M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $535.00K 10-Q · filed 2026-04-30 | $8.39M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $11.79M 10-K · filed 2026-02-26 |
| 2024-09-30 | $5.05M 10-Q · filed 2025-11-04 | $10.18M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $630.00K 10-Q · filed 2025-08-11 | $5.26M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $3.93M 10-Q · filed 2025-05-09 | $5.31M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $563.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.86M 10-K · filed 2026-02-26 |
| 2023-09-30 | $135.00K 10-Q · filed 2024-10-31 | $3.66M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $676.00K 10-Q · filed 2024-08-07 | $4.49M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.49M 10-Q · filed 2024-05-02 | $4.19M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.15M 10-K · filed 2025-02-27 |
| 2022-09-30 | $964.00K 10-Q · filed 2023-11-02 | $3.55M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $377.00K 10-Q · filed 2023-08-03 | $5.84M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $449.00K 10-Q · filed 2023-05-04 | $6.93M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $7.63M 10-K · filed 2024-02-22 |
| 2021-09-30 | $3.26M 10-Q · filed 2022-11-03 | $5.90M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $1.47M 10-Q · filed 2022-08-09 | $2.75M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $1.15M 10-Q · filed 2022-05-03 | $1.31M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $162.00K 10-K · filed 2023-02-23 |
| 2020-09-30 | $110.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $28.00K 10-Q · filed 2021-08-06 | |
| 2019-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $74.00K 10-K · filed 2022-02-24 |
| 2019-09-30 | $43.00K 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |